Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced the launch of NovoCare Pharmacy, a direct-to-patient delivery option designed to provide cash-paying patients with all dose strengths of Wegovy at a reduced cost of USD 499 per month.
Program Details
The introduction of NovoCare Pharmacy mirrors the approach taken by US major Eli Lilly & Co. (NYSE: LLY) with its Zepbound Self Pay Journey Program. This new offering from Novo Nordisk is specifically aimed at patients who pay out-of-pocket for their medications, providing them with a more affordable option for accessing Wegovy.
Market Context
Currently, over 55 million people in the US have insurance coverage that specifically includes weight management medicines. It is reported that 90% of Wegovy patients pay just USD 0 to USD 25 a month for the medication. NovoCare Pharmacy now offers an alternative for those without such coverage, allowing cash-paying patients who have been prescribed Wegovy to schedule shipments of their prescriptions directly to their homes.-Fineline Info & Tech
Leave a Reply